Significance of hepatic resection for hepatocellular carcinoma with sustained virological response to interferon therapy for chronic hepatitis C

Hepatology Research

Volumn 43, Issue 6, 2013, Pages 605-609

  Sugimachi, Keishi ^a,b   Kinjo, Nao ^a   Ikebe, Masahiko ^a   Yamashita, Naoki ^a   Kajiwara, Eiji ^a   Mimori, Koshi ^b   Higashi, Hidefumi ^a  

^a STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Hepatectomy; Hepatocellular carcinoma; Interferon; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIVIRUS AGENT; INTERFERON; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE BLOOD LOSS; INTRAOPERATIVE PERIOD; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; ONCOLOGICAL PARAMETERS; PEROPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TUMOR DIAMETER;

EID: 84878781643     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01112.x     Document Type: Article

References (20)

1. Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Intern Med 2006; 45: 229-233.
2. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235.
3. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44 (Suppl 19): 102-107.
4. Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol 2011; 9: 108.
5. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-345.
6. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
7. Chander G, Sulkowski MS, Jenckes MW etal. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S135-144.
8. Knodell RG, Ishak KG, Black WC etal. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
9. Hubscher SG. Histological grading and staging in chronic hepatitis: clinical applications and problems. J Hepatol 1998; 29: 1015-1022.
10. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
11. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
12. Japan Lcsgo. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 4th edn. Tokyo: Kanehara, 2001.
13. Shirabe K, Wakiyama S, Gion T etal. Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma - results of 152 resected cases. Hepato-gastroenterology 2007; 54: 2084-2087.
14. Shiratori Y, Ito Y, Yokosuka O etal. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-114.
15. Masuzaki R, Tateishi R, Yoshida H etal. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-1961.
16. Lin ZH, Xin YN, Dong QJ etal. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736.
17. Ikai I, Arii S, Ichida T etal. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005; 32: 163-172.
18. Ikai I, Arii S, Kojiro M etal. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
19. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol 2010; 45: 146-152.
20. Tomimaru Y, Nagano H, Eguchi H etal. Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2010; 102: 308-314.